Skip to main content

Bristol-Myers: It’s Worth the Premium, Leerink Says

Of the 21 drug makers in the S&P 500 index, Bristol-Myers Squibb ( BMY ) ends 2015 as one of the group’s strongest performing stocks. It is also one of the most expensive drug makers in the index, trading at more than 30 times 2016 earnings estimates. But according to Leerink analyst Seamus Fernandez and his team, Bristol is worth that premium. READ MORE »
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.